Supporting our research are three facilities that enable the progression of developments from the laboratory to the market. These facilities for scale-up of Biotherapeutics, Peptides, Chemical Synthesis and Drug Delivery are being upgraded on a continuous basis for higher volume capability, and with improved technology.

These facilities are currently working the progression of 20 products that have emerged from the laboratory.

Eptifibatide, the indigenously developed GP IIb/IIIa blocker, which is presently in the Indian market, is a product of this resource.